Please ensure Javascript is enabled for purposes of website accessibility

Why Moderna Stock Popped Today

By Joe Tenebruso - Apr 14, 2021 at 8:11PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The biotech has a pipeline full of promising drugs.

What happened

Shares of Moderna (MRNA -2.39%) climbed 6.9% Wednesday after the biotechnology company said it expects to have a COVID-19 booster shot available -- as well as several new vaccine candidates in clinical trials -- later this year.

So what

In late March, the National Institutes of Health (NIH) began a trial to evaluate an experimental vaccine from Moderna designed to defend against a worrisome coronavirus mutation first identified in South Africa. The goal is to develop booster shots to combat new virus variants that are resistant to Moderna's authorized COVID-19 vaccine.

"I want to make sure there are boost vaccines available in the fall so that we protect people as we go into the next fall and winter season in the U.S.," Moderna CEO Stephane Bancel told CNBC. 

People are working in a laboratory.

Moderna is ramping up its research and development efforts. Image source: Getty Images.

Moderna also said it plans to begin phase 1 studies of its messenger RNA (mRNA) flu and HIV vaccine candidates later in 2021. The biotech currently has 14 different vaccine candidates in clinical trials. 

"We believe we have a unique opportunity to develop new vaccines against viruses hurting people around the world, at a pace that is radically different from what the industry has previously done," Bancel said in a press release. "We are working to further increase our vaccine pipeline and accelerate these important programs." 

Now what 

Interestingly, Moderna intends to explore the possibility of a combination vaccine that would protect against COVID-19 and the flu. As many as 5 million people contract severe forms of the flu each year as existing flu vaccines are typically less than 60% effective. Moderna hopes to improve upon those efficacy rates and offer people the convenience of a single annual booster shot that would protect against both diseases.

"With our mRNA vaccines, we believe we have an opportunity to have a profound impact on human health," Bancel said. 

Joe Tenebruso has no position in any of the stocks mentioned. The Motley Fool recommends Moderna Inc. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Moderna, Inc. Stock Quote
Moderna, Inc.
MRNA
$146.42 (-2.39%) $-3.58

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
397%
 
S&P 500 Returns
128%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/19/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.